MYGN Stock Recent News

Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.12 per share a year ago.

Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences

Myriad Genetics demonstrates strong year-over-year growth in testing volumes and revenue in various segments of genetic testing. The company shows good management of costs and adjusts its revenue guidance, reflecting confidence in continued growth. Myriad Genetics strategically acquires assets to strengthen its operational efficiencies and position in oncology precision medicine.

Myriad Genetics (MYGN) is set to acquire certain assets of IPG, including Precise Liquid, which is expected to be launched later this year.

Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.

SALT LAKE CITY, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Myriad management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 4:30pm PST/ 7:30pm EST.

Myriad Genetics' (MYGN) new MCRR platform advances patient care by combining structured clinical data with genetic and genomic results.

Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.